TNFRSF9 and neoplasm: This strategy was taken one step further by anchoring IL-2 along with the immunostimulatory agonist anti-CD137 on the surface of stealth liposomes modified with polyethylene glycol (PEG) to improve tumor accumulation by active targeting (Figure 3A) (83).